Hepion Pharmaceuticals, Inc.
(NASDAQ : HEPA)

( )
HEPA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
6.95%20.6214.1%$121.33m
MDCOMedicines Company
-0.66%52.0120.3%$106.13m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-2.97%114.506.2%$90.18m
AMRNAmarin Corporation Plc Sponsored ADR
2.08%15.221.8%$82.95m
PRGOPerrigo Co. Plc
2.83%53.476.8%$56.22m
JAZZJazz Pharmaceuticals Plc
0.60%118.672.3%$53.75m
SAGESAGE Therapeutics, Inc.
3.37%140.558.6%$52.51m
PCRXPacira Pharmaceuticals, Inc.
2.50%37.6910.5%$44.41m
UTHRUnited Therapeutics Corporation
1.41%81.8914.3%$40.50m
CTLTCatalent Inc
2.01%48.632.4%$35.04m
HZNPHorizon Pharma plc
2.73%27.066.6%$32.50m
ICLRICON Plc
-0.20%142.184.1%$32.03m
ICPTIntercept Pharmaceuticals, Inc.
1.09%59.5516.9%$30.63m
AERIAerie Pharmaceuticals, Inc.
13.71%20.156.8%$27.15m
ENDPEndo International Plc
3.49%3.718.8%$26.10m

Company Profile

Hepion Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.